Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Other Events
Item 8.01 Other Information.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Other Events
On April 14, 2020, the slide presentation attached as Exhibit 99.1, which is incorporated herein by reference, will be presented at the Virtual Needham Healthcare Conference by the management of Cidara Therapeutics, Inc. (the “Company”). Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Cidara Therapeutics, Inc. Exhibit
EX-99.1 2 cidaracorporatepresentat.htm CORPORATE PRESENTATION cidaracorporatepresentat New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14,…
To view the full exhibit click
EX-99.1 2 cidaracorporatepresentat.htm CORPORATE PRESENTATION cidaracorporatepresentat New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14,…
To view the full exhibit click
hereAbout Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
